Details Basic Details Date Tuesday, August 27, 2019 Type Presentation Materials Utilization of Prescription Anti-Obesity Drugs in the U.S. Food and Drug Administration's (FDA) Sentinel System, 2008-2017 Additional Information Information Host 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management Related Assessment(s) Abstracts of the 35th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Pennsylvania Convention Center, Philadelphia, PA, USA, August 24‐28, 2019 Sentinel Drug Study: Anti-Obesity Medications (Benzophetamine, Bupropion/Naltrexone, Diethylpropion, Liraglutide, Lorcaserin, Orlistat, Phendimetrazine, Phentermine, Phentermine/Topiramate) & Duration of Use and Patient Characteristics Contributors Presenter(s) Sara Azimi-Bolourian, Emily C. Welch, Candace C. Fuller, Rajani Rajbhandari, Christian Hampp, Michael D. Nguyen